Skip to content


Class-leading microRNA RT-qPCR Technology

MiRXES’ patented reverse transcription (RT)-quantitative polymerase chain reaction (qPCR) technology platform enables sensitive, specific, and robust detection of microRNAs and other non-coding RNAs in biofluids and tissue samples. 

This platform has been independently validated to be more sensitive than other RT-qPCR technologies for microRNA quantification.

Play Video

Key Benefits

Increased Sensitivity

Optimized RT-qPCR primers and reagents ensure efficient target amplification from limited amounts (~1 pg) of input RNA.

Increased Specificity

No universal primers. Every assay utilizes three microRNA-specific primers to discriminate between microRNAs with single nucleotide differences.


From RNA to Ct result in less than 2 hours.


Assays optimized by our proprietary algorithm and experimentally validated.


Provided in a complete kit to minimize set-up time. Compatible with all major qPCR instruments.

How does it work?

Key Features

Unique RT Primer

Conformation-restricted microRNA-specific RT primer. Efficiently hybridizes to mature, but not precursor form, of target microRNA.

Specific Real-Time PCR Primers

microRNA-specific forward and reverse real-time PCR primers confer further specificity and enable robust amplification.

Tailored RT-qPCR Reagents

Optimized RT and qPCR master mixes that enhance signal-to-noise ratio.

Validated Class-leading Performance